Dental implants in patients under bisphosphonate therapy and the risk of osteonecrosis

• DOI: 10.22533/at.ed.1592622213105

• Palavras-chave: dental implant; bisphosphonate; osteonecrosis; osseointegration

• Keywords: dental implant; bisphosphonate; osteonecrosis; osseointegration

• Abstract:

  Oral rehabilitation with dental implants has shown a high success rate reported in the literature and with that, implantology presents itself as a safe technique, widely accepted and used. However, the implant is subject to complications from several factors at any stage of treatment, the most common being the risk of developing osteonecrosis of the jaws in patients using antiresorptive and/or antiangiogenic drugs. Bisphosphonate is a drug used in the treatment of diseases such as osteoporosis, bone metastasis from cancer, among others. It is capable of interfering with osteoclastic and osteoblastic activity, inhibit osseointegration or even delay the healing of bone tissue and consequently can negatively interact with the installation of the dental implant that needs to have osseointegration for its fixation. Even in the face of this drug interaction, although implant rehabilitation is very complex for these patients, it is not a contraindication to this treatment. It is necessary to evaluate all risks, other comorbidities, systemic diseases, deleterious habits and patient hygiene. Those who perform the installation of implants using these drugs must be monitored by the dental surgeon for possible signs of bone infection and avoid triggering bone necrosis. If this occurs, despite all precautions.